207 related articles for article (PubMed ID: 29408205)
1. Risks of Melanoma and Other Cancers in Melanoma-Prone Families over 4 Decades.
Tucker MA; Elder DE; Curry M; Fraser MC; Pichler V; Zametkin D; Yang XR; Goldstein AM
J Invest Dermatol; 2018 Jul; 138(7):1620-1626. PubMed ID: 29408205
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Longitudinal Surveillance on Tumor Thickness for Melanoma-Prone Families with and without Pathogenic Germline Variants of
Sargen MR; Pfeiffer RM; Elder DE; Yang XR; Goldstein AM; Tucker MA
Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):676-681. PubMed ID: 33811164
[TBL] [Abstract][Full Text] [Related]
3. Pediatric melanoma in melanoma-prone families.
Goldstein AM; Stidd KC; Yang XR; Fraser MC; Tucker MA
Cancer; 2018 Sep; 124(18):3715-3723. PubMed ID: 30207590
[TBL] [Abstract][Full Text] [Related]
4. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden).
Vasen HF; Gruis NA; Frants RR; van Der Velden PA; Hille ET; Bergman W
Int J Cancer; 2000 Sep; 87(6):809-11. PubMed ID: 10956390
[TBL] [Abstract][Full Text] [Related]
5. A natural history of melanomas and dysplastic nevi: an atlas of lesions in melanoma-prone families.
Tucker MA; Fraser MC; Goldstein AM; Struewing JP; King MA; Crawford JT; Chiazze EA; Zametkin DP; Fontaine LS; Clark WH
Cancer; 2002 Jun; 94(12):3192-209. PubMed ID: 12115352
[TBL] [Abstract][Full Text] [Related]
6. Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Low to Moderate Incidence: The Rule of 2 vs the Rule of 3.
Delaunay J; Martin L; Bressac-de Paillerets B; Duru G; Ingster O; Thomas L
JAMA Dermatol; 2017 Nov; 153(11):1122-1129. PubMed ID: 28903138
[TBL] [Abstract][Full Text] [Related]
7. Characterization of ligurian melanoma families and risk of occurrence of other neoplasia.
Ghiorzo P; Ciotti P; Mantelli M; Heouaine A; Queirolo P; Rainero ML; Ferrari C; Santi PL; De Marchi R; Farris A; Ajmar F; Bruzzi P; Bianchi-Scarrà G
Int J Cancer; 1999 Nov; 83(4):441-8. PubMed ID: 10508477
[TBL] [Abstract][Full Text] [Related]
8. Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.
Potrony M; Puig-Butillé JA; Aguilera P; Badenas C; Carrera C; Malvehy J; Puig S
J Am Acad Dermatol; 2014 Nov; 71(5):888-95. PubMed ID: 25064638
[TBL] [Abstract][Full Text] [Related]
9. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.
Goldstein AM; Struewing JP; Chidambaram A; Fraser MC; Tucker MA
J Natl Cancer Inst; 2000 Jun; 92(12):1006-10. PubMed ID: 10861313
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for melanoma incidence in prospective follow-up. The importance of atypical (dysplastic) nevi.
Schneider JS; Moore DH; Sagebiel RW
Arch Dermatol; 1994 Aug; 130(8):1002-7. PubMed ID: 8053695
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic cancer-associated gene polymorphisms in a nation-wide cohort of p16-Leiden germline mutation carriers; a case-control study.
Potjer TP; van der Stoep N; Houwing-Duistermaat JJ; Konings IC; Aalfs CM; van den Akker PC; Ausems MG; Dommering CJ; van der Kolk LE; Maiburg MC; Spruijt L; Wagner A; Vasen HF; Hes FJ
BMC Res Notes; 2015 Jun; 8():264. PubMed ID: 26111702
[TBL] [Abstract][Full Text] [Related]
12. Surveillance of second-degree relatives from melanoma families with a CDKN2A germline mutation.
van der Rhee JI; Boonk SE; Putter H; Cannegieter SC; Flinterman LE; Hes FJ; de Snoo FA; Mooi WJ; Gruis NA; Vasen HF; Kukutsch NA; Bergman W
Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1771-7. PubMed ID: 23897584
[TBL] [Abstract][Full Text] [Related]
13. Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (P16INK4A) gene.
Puig S; Ruiz A; Castel T; Volpini V; Malvehy J; Cardellach F; Lynch M; Mascaro JM; Estivill X
Hum Genet; 1997 Dec; 101(3):359-64. PubMed ID: 9439668
[TBL] [Abstract][Full Text] [Related]
14. Swedish CDKN2A mutation carriers do not present the atypical mole syndrome phenotype.
Nielsen K; Harbst K; Måsbäck A; Jönsson G; Borg A; Olsson H; Ingvar C
Melanoma Res; 2010 Aug; 20(4):266-72. PubMed ID: 20526219
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of kindreds with hereditary predisposition for cutaneous melanoma and dysplastic nevus syndrome: results of a Swedish preventive program.
Hansson J; Bergenmar M; Hofer PA; Lundell G; Månsson-Brahme E; Ringborg U; Synnerstad I; Bratel AT; Wennberg AM; Rosdahl I
J Clin Oncol; 2007 Jul; 25(19):2819-24. PubMed ID: 17602087
[TBL] [Abstract][Full Text] [Related]
16.
Pissa M; Helkkula T; Appelqvist F; Silander G; Borg Å; Pettersson J; Lapins J; Nielsen K; Höiom V; Helgadottir H
Acta Oncol; 2021 Jul; 60(7):888-896. PubMed ID: 33945383
[No Abstract] [Full Text] [Related]
17. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants.
Puntervoll HE; Yang XR; Vetti HH; Bachmann IM; Avril MF; Benfodda M; Catricalà C; Dalle S; Duval-Modeste AB; Ghiorzo P; Grammatico P; Harland M; Hayward NK; Hu HH; Jouary T; Martin-Denavit T; Ozola A; Palmer JM; Pastorino L; Pjanova D; Soufir N; Steine SJ; Stratigos AJ; Thomas L; Tinat J; Tsao H; Veinalde R; Tucker MA; Bressac-de Paillerets B; Newton-Bishop JA; Goldstein AM; Akslen LA; Molven A
J Med Genet; 2013 Apr; 50(4):264-70. PubMed ID: 23384855
[TBL] [Abstract][Full Text] [Related]
18. Dysplastic nevi and other risk markers for melanoma.
Seykora J; Elder D
Semin Oncol; 1996 Dec; 23(6):682-7. PubMed ID: 8970587
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome.
Lynch HT; Brand RE; Hogg D; Deters CA; Fusaro RM; Lynch JF; Liu L; Knezetic J; Lassam NJ; Goggins M; Kern S
Cancer; 2002 Jan; 94(1):84-96. PubMed ID: 11815963
[TBL] [Abstract][Full Text] [Related]
20. Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas.
Helsing P; Nymoen DA; Ariansen S; Steine SJ; Maehle L; Aamdal S; Langmark F; Loeb M; Akslen LA; Molven A; Andresen PA
Genes Chromosomes Cancer; 2008 Feb; 47(2):175-84. PubMed ID: 18023021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
